LeMaitre Vascular (LMAT) News Today

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and o

LeMaitre Vascular (NASDAQ:LMAT) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=437996)

StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Thursday.

LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month High at $88.86

Scout Investments Inc. decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 6.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 169,329 shares of the medical instruments supplier's stock after selling 10,777 shares during

ProShare Advisors LLC decreased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 20.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 113,911 shares of the medical instruments supplier's stock after

Quantbot Technologies LP boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1,001.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,335 shares of the medical instruments supplier's

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) CEO George W. Lemaitre sold 12,976 shares of the business's stock in a transaction on Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the sale, the chief executive officer now owns 1,985,358 shares in the company, valued at $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

LeMaitre Vascular (NASDAQ:LMAT) Sets New 12-Month High at $86.77

LeMaitre Vascular (NASDAQ:LMAT) Sets New 12-Month High at $84.19

Vanguard Group Inc. boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 2.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,548,870 shares of the medical instruments supplier's stock after

Congress Wealth Management LLC DE grew its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 27.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,986 shares of the medical instruments supplier's stock after

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have iss

Congress Asset Management Co. MA raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 12.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 666,083 shares of the medical instruments supplier'

StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday.

LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High at $81.68

Congress Asset Management Co. MA boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 594,672 shares of the me

Ranger Investment Management L.P. increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 912,503 shares of the

Annex Advisory Services LLC lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 105.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 24,834 shares of the medical instruments supplier's stock after acquiring an additional

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Research analysts at Roth Capital issued their Q1 2025 earnings estimates for shares of LeMaitre Vascular in a research report issued on Friday, May 31st. Roth Capital analyst J. Wittes anticipates that the medical instruments supplier will po

Roth Mkm restated a "buy" rating and set a $100.00 price target on shares of LeMaitre Vascular in a report on Friday.

Trexquant Investment LP cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 34.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,738 shares of the medical instruments supplier's stock after selling 10,595

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director Bridget A. Ross sold 5,500 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total transaction of $428,945.00. Following the sale, the director now directly owns 2,278 shares of the company's stock, valued at approximately $177,661.22. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

LeMaitre Vascular (NASDAQ:LMAT) Reaches New 12-Month High at $79.41

Summit Creek Advisors LLC increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 37.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 228,501 shares of the medical instruments supplier's stoc

LeMaitre Vascular (NASDAQ:LMAT) Reaches New 52-Week High at $76.26

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Tuesday, April 30th. Stockholders of record on Thursday, May 16th will be given a dividend of 0.16 per share by the medical instruments supplier on Thursday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Wednesday, May 15th.

Mesirow Institutional Investment Management Inc. bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 155,682 shares of the medical

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The sale was disclosed in a legal filing with the SEC, which is available at this link.

LeMaitre Vascular (NASDAQ:LMAT) Hits New 1-Year High on Analyst Upgrade

Russell Investments Group Ltd. raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 6.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 288,212 shares of the medical instruments supplier's stock after acquiring an

StockNews.com raised LeMaitre Vascular from a "hold" rating to a "buy" rating in a research note on Friday.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) issued its earnings results on Thursday. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The business had revenue of $53.48 million for the quarter, compared to analysts' expectations of $51.50 million. During the same period in the previous year, the firm posted $0.27 EPS. The business's revenue for the quarter was up 13.6% compared to the same quarter last year.

JMP Securities increased their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a "market outperform" rating in a report on Friday.